(Q35842690)

10 August 2017

1 reference

title

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab (English)

1 reference

10 August 2017

1 reference

1 reference

Jonathan S Berek

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

7

1 reference

10 August 2017

page(s)

1159-1165

1 reference

10 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Rituximab: ongoing and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.7.1159

10.1517/14712598.4.7.1159

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference